Prostate cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PSMA 271
• AR 15
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• HDAC 0
• IL-15 4
• METTL3 1
• ATM 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 80+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Updated 6 Nov 2026

  “Difficulties in patient recruitment”Registry text, quoted unchanged. Source

• Withdrawn

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

  NCT05960578· University of Washington· Updated 19 Oct 2026

  “The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

  NCT06982222· National Cancer Institute (NCI)· Updated 28 Aug 2026

  “Other - Protocol moved to Withdrawn”Registry text, quoted unchanged. Source

• Suspended

  Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

  NCT06200103· Mayo Clinic· Updated 20 Aug 2026

  “Pending additional funding.”Registry text, quoted unchanged. Source

• Terminated

  Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

  NCT05995236· Methodist Health System· Updated 4 Aug 2026

  “So far, we have not been able to collect meaningful data for these patients which also led to our decision to close this study before attempting write up and publish any results”Registry text, quoted unchanged. Source

• Terminated

  High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

  NCT04461509· Alessandro D'Agnolo· Updated 22 Jul 2026

  “Funding ceased before all specimen collection and analysis could be completed”Registry text, quoted unchanged. Source

• Suspended

  Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

  NCT05422105· Primo Biotechnology Co., Ltd· Updated 6 Jul 2026

  “Interim Analysis”Registry text, quoted unchanged. Source

• Terminated

  Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

  NCT04745871· University Hospital, Brest· Updated 11 Jun 2026

  “In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today, PSMA PET/CT has become routine and is performed before MTB review.”Registry text, quoted unchanged. Source

• Terminated

  68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

  NCT04716725· Thomas Hope· Updated 15 May 2026

  “Low accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

  NCT06004661· Novartis Pharmaceuticals· Source

• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Novartis Pharmaceuticals· Source

• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Novartis Pharmaceuticals· Source

• Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

  NCT07914855· National Cancer Institute (NCI)· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  NCT06095089· Janssen Research & Development, LLC· Source

• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Janssen Research & Development, LLC· Source

• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Janssen Pharmaceutica N.V., Belgium· Source

• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

  NCT03181867· National Cancer Institute (NCI)· Source

• Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

  NCT05683964· Beth Israel Deaconess Medical Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 152
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 31
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 124
• Magnetic Resonance Imaging 460
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 275
• Genome-Wide Association Study 60

See which targets of this disease your abstract mentions, and go to the people working on them.